Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 6, 2024
Reporting Period: Unaudited results for the three and six months ended June 30, 2024.
This filing serves to announce the Second Quarter 2024 earnings results and includes a reconciliation of non-GAAP financial measures. The full press release is attached as Exhibit 99.1.
Key Financial Metrics
Note: The provided text is a cover filing (Form 8-K) and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced press release (Exhibit 99.1).
The filing highlights the following financial measures presented in the accompanying press release:
- GAAP Measures: Net income, operating income, and operating cash flow.
- Non-GAAP Measures: Non-GAAP earnings per share, operating income, operating margin, tax rate, net income, other income (expense), interest expense, and operating expenses (including cost of sales, R&D, and SG&A).
- Liquidity Measure: Free Cash Flow (FCF), calculated as operating cash flow minus capital expenditures.
Material Changes and Adjustments
The filing details specific items excluded from GAAP results to calculate non-GAAP measures, which may impact period-over-period comparisons:
- Acquisition-related expenses: Amortization of intangible assets (e.g., developed-product-technology rights, licensing rights) and step-up to fair value of acquired inventory. These vary based on acquisition timing and product approvals.
- Restructuring and cost savings: Facilities charges, asset impairments, accelerated depreciation, and severance/benefits related to transformation efforts.
- Other items: Gains/losses on equity securities, legal settlement judgments, and specific debt-related costs (interest and fees) associated with the Horizon Therapeutics acquisition.
Guidance, Outlook, and Management Commentary
Management Usage: Management utilizes non-GAAP measures for internal budgeting, financial planning, resource allocation, and evaluating performance against incentive compensation targets. They believe these measures facilitate better comparisons of ongoing business operations across periods.
Forward-Looking Information: The text does not contain specific numerical guidance or outlook figures for future periods. It notes that the information in the press release is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1: Verify specific revenue, net income, and EPS figures in the attached press release, as they are not listed in this 8-K text.
- Reconciliation Analysis: Examine the reconciliation tables in the press release to understand the magnitude of adjustments between GAAP and non-GAAP results, particularly regarding Horizon Therapeutics acquisition costs.
- Free Cash Flow: Confirm the calculation of FCF (Operating Cash Flow less Capital Expenditures) to assess liquidity.
- Acquisition Impact: Assess the variability of amortization charges related to intangible assets, which the company notes can significantly impact net charges period-to-period.